1
|
Cattell M, Hyde K, Bell B, Dawson T, Hills T, Iyen B, Khimji A, Avery A. Retrospective review of medication-related incidents at a major teaching hospital and the potential mitigation of these incidents with electronic prescribing and medicines administration. Eur J Hosp Pharm 2024; 31:295-300. [PMID: 36868849 PMCID: PMC11228223 DOI: 10.1136/ejhpharm-2022-003515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Accepted: 02/06/2023] [Indexed: 03/05/2023] Open
Abstract
OBJECTIVES To describe the frequency of the different types of medication-related incidents that caused patient harm, or adverse consequences, in a major teaching hospital and investigate whether the likelihood of these incidents occurring would have been reduced by electronic prescribing and medicines administration (EPMA). METHODS A retrospective review of harmful incidents (n=387) was completed for medication-related reports at the hospital between 1 September 2020 and 31 August 2021. Frequencies of different types of incidents were collated. The potential for EPMA to have prevented these incidents was assessed by reviewing DATIX reports and additional information, including results of any investigations. RESULTS The largest proportion of harmful medication incidents were administration related (n=215, 55.6%), followed by incidents classified as 'other' and 'prescribing'. Most incidents were classified as low harm (n=321, 83.0%). EPMA could have reduced the likelihood of all incidents which caused harm by 18.6% (n=72) without configuration, and a further 7.5% (n=29) with configuration where configuration refers to adapting the software's functionality without supplier input or development. For 18.4% of the low-harm incidents (n=59) and 20.3% (n=13) of the moderate-harm incidents, EPMA could reduce the likelihood of the incident occurring without configuration. Medication errors most likely to be reduced by EPMA were due to illegibility, multiple drug charts or missing drug charts. CONCLUSION This study found that administration incidents were the most common type of medication-related incidents. Most of the incidents (n=243, 62.8%) could not be mitigated by EPMA in any circumstance, even with connectivity between technologies. EPMA has the potential to prevent certain types of harmful medication-related incidents, and further improvements could be achieved with configuration and development.
Collapse
Affiliation(s)
| | - Kira Hyde
- University of Nottingham, Nottingham, UK
| | - Brian Bell
- University of Nottingham, Nottingham, UK
| | - Thomas Dawson
- Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Tim Hills
- Nottingham University Hospitals NHS Trust, Nottingham, UK
| | | | | | | |
Collapse
|
2
|
Sibicky SL, Pogge EK, Bouwmeester CJ, Butterfoss KH, Ulen KR, Meyer KS. Pharmacists' Impact on Older Adults Transitioning To and From Patient Care Centers: A Scoping Review. J Pharm Pract 2024; 37:169-183. [PMID: 36062533 DOI: 10.1177/08971900221125014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective: Expand upon previous reviews conducted on transitions of care (TOC) services with a focus on pharmacist interventions for older adults specifically transitioning to and from long-term care, acute rehabilitation, residential care facilities, care homes, skilled nursing, or assisted living facilities, collectively termed patient care centers (PCC). Data Sources: A PubMed and Ovid MEDLINE search was conducted including citations between 1974 and July 14, 2022. Bibliographies were also reviewed for additional citations. Methods: Articles included described pharmacist interventions during TOC for patients transitioning to and from PCC, were written in English, and reported outcomes pertaining to TOC services. Of 873 citations reviewed, 22 articles met the inclusion criteria. Results: Most studies were prospective in design with small sample sizes, of limited duration, and with varying interventions and reported outcomes. Most explored the transition from hospital to PCC and included a pharmacist intervention involving the identification of medication errors and discrepancies during the TOC. Few studies reported cost savings or 30- and 60-day reductions in readmission rates or mortality. Conclusions: This scoping review revealed a lack of robust clinical trials to assess the effectiveness of specific interventions performed by pharmacists for patients transitioning to and from PCC. Of the available data, pharmacist involvement within an interprofessional team can be an effective intervention to resolve medication discrepancies, reduce readmissions, and medication-related adverse events. An opportunity exists for future studies to explore ways to improve outcomes during TOC within PCC.
Collapse
Affiliation(s)
- Stephanie L Sibicky
- Department of Pharmacy and Health Systems Sciences, School of Pharmacy and Pharmaceutical Sciences, Northeastern University, Boston, MA, USA
| | - Elizabeth K Pogge
- College of Pharmacy - Glendale Campus, Midwestern University, Glendale, AZ, USA
| | - Carla J Bouwmeester
- Department of Pharmacy and Health Systems Sciences, School of Pharmacy and Pharmaceutical Sciences, Northeastern University, Boston, MA, USA
| | | | - Kelly R Ulen
- Department of Geriatrics, UPSTATE Community Hospital, Syracuse, NY, USA
| | - Kristin S Meyer
- College of Pharmacy and Health Sciences, Drake University, Des Moines, IA, USA
| |
Collapse
|
3
|
Langenberger B. Machine learning as a tool to identify inpatients who are not at risk of adverse drug events in a large dataset of a tertiary care hospital in the USA. Br J Clin Pharmacol 2023; 89:3523-3538. [PMID: 37430382 DOI: 10.1111/bcp.15846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Revised: 07/03/2023] [Accepted: 07/06/2023] [Indexed: 07/12/2023] Open
Abstract
AIMS Adverse drug events (ADEs) are a major threat to inpatients in the United States of America (USA). It is unknown how well machine learning (ML) is able to predict whether or not a patient will suffer from an ADE during hospital stay based on data available at hospital admission for emergency department patients of all ages (binary classification task). It is further unknown whether ML is able to outperform logistic regression (LR) in doing so, and which variables are the most important predictors. METHODS In this study, 5 ML models- namely a random forest, gradient boosting machine (GBM), ridge regression, least absolute shrinkage and selection operator (LASSO) regression, and elastic net regression-as well as a LR were trained and tested for the prediction of inpatient ADEs identified using ICD-10-CM codes based on comprehensive previous work in a diverse population. In total, 210 181 observations from patients who were admitted to a large tertiary care hospital after emergency department stay between 2011 and 2019 were included. The area under the receiver operating characteristics curve (AUC) and AUC-precision-recall (AUC-PR) were used as primary performance indicators. RESULTS Tree-based models performed best with respect to AUC and AUC-PR. The gradient boosting machine (GBM) reached an AUC of 0.747 (95% confidence interval (CI): 0.735 to 0.759) and an AUC-PR of 0.134 (95% CI: 0.131 to 0.137) on unforeseen test data, while the random forest reached an AUC of 0.743 (95% CI: 0.731 to 0.755) and an AUC-PR of 0.139 (95% CI: 0.135 to 0.142), respectively. ML statistically significantly outperformed LR both on AUC and AUC-PR. Nonetheless, overall, models did not differ much with respect to their performance. Most important predictors were admission type, temperature and chief complaint for the best performing model (GBM). CONCLUSIONS The study demonstrated a first application of ML to predict inpatient ADEs based on ICD-10-CM codes, and a comparison with LR. Future research should address concerns arising from low precision and related problems.
Collapse
Affiliation(s)
- Benedikt Langenberger
- Department of Health Care Management, Technische Universität Berlin, Berlin, Germany
| |
Collapse
|
4
|
Calvo-Cidoncha E, Camacho-Hernando C, Feu F, Pastor-Duran X, Codina-Jané C, Lozano-Rubí R. OntoPharma: ontology based clinical decision support system to reduce medication prescribing errors. BMC Med Inform Decis Mak 2022; 22:238. [PMID: 36088328 PMCID: PMC9463735 DOI: 10.1186/s12911-022-01979-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Accepted: 08/25/2022] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
Clinical decision support systems (CDSS) have been shown to reduce medication errors. However, they are underused because of different challenges. One approach to improve CDSS is to use ontologies instead of relational databases. The primary aim was to design and develop OntoPharma, an ontology based CDSS to reduce medication prescribing errors. Secondary aim was to implement OntoPharma in a hospital setting.
Methods
A four-step process was proposed. (1) Defining the ontology domain. The ontology scope was the medication domain. An advisory board selected four use cases: maximum dosage alert, drug-drug interaction checker, renal failure adjustment, and drug allergy checker. (2) Implementing the ontology in a formal representation. The implementation was conducted by Medical Informatics specialists and Clinical Pharmacists using Protégé-OWL. (3) Developing an ontology-driven alert module. Computerised Physician Order Entry (CPOE) integration was performed through a REST API. SPARQL was used to query ontologies. (4) Implementing OntoPharma in a hospital setting. Alerts generated between July 2020/ November 2021 were analysed.
Results
The three ontologies developed included 34,938 classes, 16,672 individuals and 82 properties. The domains addressed by ontologies were identification data of medicinal products, appropriateness drug data, and local concepts from CPOE. When a medication prescribing error is identified an alert is shown. OntoPharma generated 823 alerts in 1046 patients. 401 (48.7%) of them were accepted.
Conclusions
OntoPharma is an ontology based CDSS implemented in clinical practice which generates alerts when a prescribing medication error is identified. To gain user acceptance OntoPharma has been designed and developed by a multidisciplinary team. Compared to CDSS based on relational databases, OntoPharma represents medication knowledge in a more intuitive, extensible and maintainable manner.
Collapse
|
5
|
Mader JK, Aberer F, Drechsler KS, Pöttler T, Lichtenegger KM, Köle W, Sendlhofer G. Medication errors in type 2 diabetes from patients’ perspective. PLoS One 2022; 17:e0267570. [PMID: 35482748 PMCID: PMC9049508 DOI: 10.1371/journal.pone.0267570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Accepted: 04/11/2022] [Indexed: 11/24/2022] Open
Abstract
Introduction Drug errors pose a major health hazard to a number of patient populations. However, patients with type 2 diabetes mellitus seem especially vulnerable to this risk as diabetes mellitus is usually concomitant with various comorbidities and polypharmacy, which present significant risk factors for the occurrence of drug errors. Despite this fact, there is little data on drug errors from patients’ perspective. The present survey aimed to examine the viewpoints of patients with type 2 diabetes mellitus regarding their experiences with medication errors, the overall treatment satisfaction, and their perceptions on how a medication error was handled in daily hospital routine. Materials and methods Inpatients at the Department of Endocrinology and Diabetology of the University Hospital of Graz were included in the survey. Out of 100 patients, one-half had insulin therapy before hospitalization while the other half had no insulin therapy prior to admission. After giving informed consent, patients filled out a questionnaire with 22 items. Results Independent of their preexisting therapy, 25% of patients already suffered at least one drug error, whereby prescribing a wrong dose seemed to be the most common type of error. Furthermore, 26% of patients in the non-insulin versus 50% in the insulin group (p = 0.084) were convinced that drug errors were addressed honestly by the medical staff, while 54% in the non-insulin versus 80% in the insulin-group (p = 0.061) assumed that adequate measures were taken to prevent drug errors. Finally, 9 out of 10 patients seemed satisfied with their treatment regardless of their diabetes therapy. Discussion/conclusion The results of the survey clearly showed that patients experienced at least one medication error during hospitalization. However, these errors only rarely led to patient harm. The survey also revealed the value of an honest and respectful doctor-patient relationship regarding patient perception of medication errors and general complaints. Increasing patient awareness on the existing in-hospital error management systems could eliminate treatment-related concerns and create a climate of trust that is essential for effective treatment.
Collapse
Affiliation(s)
- Julia K. Mader
- Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Styria, Austria
| | - Felix Aberer
- Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Styria, Austria
| | - Kerstin Sarah Drechsler
- Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Styria, Austria
| | - Tina Pöttler
- Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Styria, Austria
| | - Katharina M. Lichtenegger
- Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Styria, Austria
| | - Wolfgang Köle
- Department of General Otorhinolaryngology, Medical University of Graz, Graz, Austria
- Medical Directorate, University Hospital of Graz, Graz, Styria, Austria
| | - Gerald Sendlhofer
- Executive Department for Quality and Risk Management, University Hospital of Graz, Graz, Styria, Austria
- Department of Surgery, Research Unit for Safety and Sustainability in Healthcare, c/o Division of Plastic, Aesthetic and Reconstructive Surgery, Medical University of Graz, Graz, Styria, Austria
- * E-mail:
| |
Collapse
|
6
|
Alghamdi A, Alhulaylah F, Al-Qahtani F, Alsallal D, Alshabanat N, Alanazi H, Alshehri G. Evaluation of Pharmacy Intern-led Transition of Care Service at an Academic Hospital in Saudi Arabia: A Prospective Pilot Study. Saudi Pharm J 2022; 30:629-634. [PMID: 35693446 PMCID: PMC9177444 DOI: 10.1016/j.jsps.2022.02.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Accepted: 02/10/2022] [Indexed: 11/23/2022] Open
Abstract
Objectives The transition of patients from one setting to another increases the risk of medication errors (MEs). This study aims to assess the implementation of pharmacy intern-led transition of care (TOC) service and to demonstrate its impact on the quality of patient care. Method A prospective interventional pilot study was carried out from August 2020 to April 2021 at an academic hospital in Saudi Arabia. The TOC team consisted of three pharmacy interns and one pharmacist-in-charge. Daily activities included medication reconciliation, discharge counseling, and follow-up call after 3 days of discharge. The identified discrepancies were categorized according to the National Coordinating Council for Medication Error Reporting Program. Key findings A total of 182 patients were included in the analysis. During medication reconciliation, 102 discrepancies were detected, with an average of 0.7 discrepancy per patient. The most common discrepancy at admission and discharge was omission (41.7% and 70%, respectively). Category B was the most frequent and accounted for 46% at admission and 93% at discharge. Around 39% of TOC beneficiaries received a follow-up call, and all reported a high level of satisfaction with the service. Conclusion Involving the pharmacy team in TOC activities was effective in identifying discrepancies and resolving MEs.
Collapse
|
7
|
Marufu TC, Bower R, Hendron E, Manning JC. Nursing interventions to reduce medication errors in paediatrics and neonates: Systematic review and meta-analysis. J Pediatr Nurs 2022; 62:e139-e147. [PMID: 34507851 DOI: 10.1016/j.pedn.2021.08.024] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 08/26/2021] [Accepted: 08/27/2021] [Indexed: 11/16/2022]
Abstract
BACKGROUND Medication errors are a great concern to health care organisations as they are costly and pose a significant risk to patients. Children are three times more likely to be affected by medication errors than adults with medication administration error rates reported to be over 70%. OBJECTIVE To identify nursing interventions to reduce medication administration errors and perform a meta-analysis. METHODS Online databases; British Nursing Index (BNI), Cochrane Database of Systematic Reviews, Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE and MEDLINE were searched for relevant studies published between January 2000 to 2020. Studies with clear primary or secondary aims focusing on interventions to reduce medication administration errors in paediatrics, children and or neonates were included in the review. RESULTS 442 studies were screened and18 studies met the inclusion criteria. Seven interventions were identified from included studies; education programmes, medication information services, clinical pharmacist involvement, double checking, barriers to reduce interruptions during drug calculation and preparation, implementation of smart pumps and improvement strategies. Educational interventional aspects were the most common identified in 13 out of 18 included studies. Meta-analysis demonstrated an associated 64% reduction in medicine administration errors post intervention (pooled OR 0.36 (95% Confidence Interval (CI) 0.21-0.63) P = 0.0003). CONCLUSION Medication safety education is an important element of interventions to reduce administration errors. Medication errors are multifaceted that require a bundle interventional approach to address the complexities and dynamics relevant to the local context. It is imperative that causes of errors need to be identified prior to implementation of appropriate interventions.
Collapse
Affiliation(s)
- Takawira C Marufu
- Nottingham Childrens Hospital, Nottingham University Hospitals NHS Trust, Nottingham, UK.
| | - Rachel Bower
- Nottingham Childrens Hospital, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Elizabeth Hendron
- Library Services, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Joseph C Manning
- Nottingham Childrens Hospital, Nottingham University Hospitals NHS Trust, Nottingham, UK; Children and Young People Health Research, School of Health Sciences, University of Nottingham, Nottingham, UK
| |
Collapse
|
8
|
Adverse drug events during transitions of care : Randomized clinical trial of medication reconciliation at hospital admission. Wien Klin Wochenschr 2021; 134:130-138. [PMID: 34817667 DOI: 10.1007/s00508-021-01972-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Accepted: 10/18/2021] [Indexed: 10/19/2022]
Abstract
BACKGROUND During transitions of care, patient's medications are prone to medication errors. This study evaluated the impact of pharmacist-led medication reconciliation at hospital admission on unintentional medication discrepancies and adverse drug events. METHODS A randomized controlled clinical trial was conducted in 120 adult medical patients hospitalized in a tertiary hospital in Slovenia. In the intervention group, a pharmacist-led medication reconciliation was performed on admission, while the control group received usual care. Patient's drug treatment before admission was compared with their admission and inpatient treatment to identify discrepancies. The intention of discrepancies and related adverse drug events were assessed as a consensus of an expert panel. RESULTS Included patients were elderly (median 72 years) and treated with polypharmacy (median 7 medications). Upon admission, discrepancies and unintentional discrepancies, representing a medication error, were identified in 61.2% (825/1347) and 18.3% (247/1347) of medications, respectively. In the intervention group, only 29.1% (37/127) of unintentional discrepancies were reported to the physicians in person. The majority of admission discrepancies (88%) persisted through hospitalization. Unintentional discrepancies resulted in 51 adverse drug events even during hospitalization. There were no differences between the intervention and control group in the occurrence of unintentional discrepancies (p = 0.481) or adverse drug events (p = 0.801). CONCLUSIONS Medication reconciliation at hospital admission failed to reduce unintentional discrepancies and adverse drug events, possibly due to its poor integration into clinical practice. Discrepancies resulted in patient harm even during the short period of hospitalization, which warrants the implementation of medication reconciliation at hospital admission.
Collapse
|
9
|
Patel TK, Patel PB, Bhalla HL, Kishore S. Drug-related deaths among inpatients: a meta-analysis. Eur J Clin Pharmacol 2021; 78:267-278. [PMID: 34661726 DOI: 10.1007/s00228-021-03214-w] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Accepted: 09/01/2021] [Indexed: 11/26/2022]
Abstract
PURPOSE To estimate the prevalence of drug-related deaths with regard to total hospital mortality and to explore the heterogeneity in its estimation through subgroup analysis, univariate and multivariate analysis. METHODS Two investigators independently searched the PubMed and Google Scholar databases with appropriate key terms to identify observational and randomised studies assessing drug-related problems. The prevalence of drug-related deaths was estimated using a double arcsine method. The heterogeneity was explored through subgroup and univariate analysis for the following study characteristics: study design, age group, study ward, study region, types of drug-related problems, study duration, sample size and study period. The study variables showing significant effects were further explored through a multivariable regression model. The percentage of preventable drug-related deaths was explored as a secondary objective. RESULTS Of the 480 full-text articles assessed, 23 studies satisfying the selection criteria were included. The mean percentage of drug-related deaths was 5.6% (95% CI: 3.8-7.6%; I2 = 96%). The univariable analysis showed study design (regression coefficient: 4.31) and study wards (regression coefficient: - 6.37) as heterogeneity modifiers. In the multivariable model, only the study ward was considered a significant predictor of drug-related deaths (regression coefficient: - 5.78; p = 0.04). The mean percentage of preventable drug-related deaths was 45.2% (95% CI: 33.6-57.0%; I2 = 60%). CONCLUSION Drug-related problems are an important cause of mortality. The variability in its estimation could be explained by admission wards.
Collapse
Affiliation(s)
- Tejas K Patel
- Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur, Gorakhpur, Uttar Pradesh, 273008, India.
| | - Parvati B Patel
- Department of Pharmacology, GMERS Medical College, Gotri, Vadodara, Gujarat, 390021, India
| | - Hira Lal Bhalla
- Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur, Gorakhpur, Uttar Pradesh, 273008, India
| | - Surekha Kishore
- All India Institute of Medical Sciences, Gorakhpur, Gorakhpur, Uttar Pradesh, 273008, India
| |
Collapse
|
10
|
AlAhmad MM, Majed I, Sikh N, AlAhmad K. The impact of community-pharmacist-led medication reconciliation process: Pharmacist-patient-centered medication reconciliation. J Pharm Bioallied Sci 2020; 12:177-182. [PMID: 32742117 PMCID: PMC7373110 DOI: 10.4103/jpbs.jpbs_55_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Revised: 02/06/2020] [Accepted: 02/16/2020] [Indexed: 11/17/2022] Open
Abstract
Background and Purpose: Patients and their healthcare providers’ are in need to access a correct and complete list of all patients’ active bills for safe and effective clinical care. Currently, Healthcare Information Systems are not providing a proper access to the patients’ medications lists. Thus, this study aimed to evaluate the impact of community pharmacist-led medication reconciliation process in community pharmacies in the UAE through applying a pharmacist–patient-centered medication reconciliation (PPCMR). Materials and Methods: This was an interventional study of medication reconciliation process in 25 pharmacies in the UAE during July 1, 2019 till September 1, 2019. The participant pharmacists were surveyed and interviewed to gather more information about the barriers and enablers of the process before and after the implementation of PPCMR. Results: After the implementation of PPCMR, medication reconciliation service was available in 84% of the pharmacies compared to 40% before the PPCMR (Z = –2.84, P = 0.005). The main workforce barriers to implement this service were reduced to 27% compared to 47% before the PPCMR. The operational barriers for the service were decreased from 56% to 28%. The facilitators in delivering the service in community pharmacies were improved from 29% to 63%. The active collaboration between the pharmacists and physicians was enhanced from 28% to 72% (Z = –3.2, P = 0.001) in the participated pharmacies. There is a statistically significant difference toward the impact of the PPCMR on the whole medication reconciliation service χ2(df = 3) = 200, P < 0.001. Conclusion: Community pharmacists are not always accessible or well placed to provide a medication reconciliation service. The implementation of PPCMR in each community pharmacy will raise the expectations regarding the appropriateness of medication management and use.
Collapse
Affiliation(s)
- Mohammad M AlAhmad
- Department of Clinical Pharmacy, College of Pharmacy, Al Ain University, Al Ain, UAE
| | - Iqbal Majed
- Department of Pharmacy, Look Wow One Day Surgery Pharmacy, Al Ain, UAE
| | - Nour Sikh
- Department of Pharmacy, Alkhatib Medical Center, Al Ain University, Al Ain, UAE
| | - Khozama AlAhmad
- Department of Pharmacy, Mediclinic Al Ain Hospital, Al Ain, UAE
| |
Collapse
|
11
|
Adverse drug reactions that arise from the use of medicinal products outside the terms of the marketing authorisation. Res Social Adm Pharm 2020; 16:928-934. [DOI: 10.1016/j.sapharm.2019.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Revised: 10/01/2019] [Accepted: 10/06/2019] [Indexed: 10/25/2022]
|
12
|
Abstract
OBJECTIVES Medication errors and adverse drug events are a key concern of the health-care industry. The objectives of this study were to map the intellectual structure of the studies of medication errors and adverse drug events and to investigate the developing path of this literature and interrelationships among the main topics. METHODS The Web of Science database was searched for documentation of medication errors and adverse drug events from 1961 to 2013. The most cited articles and references were profiled and analyzed using HistCite software to draw a historiograph and Ucinet software to draw a sociogram. RESULTS The database search revealed 3343 medication errors and 3342 adverse drug event documents. The most cited articles on medication errors focused on 3 key themes from 1961 to 2013, namely, medication errors in adult inpatients, computerized physician order entry in medication error studies, and medication errors in pediatric inpatients. The developing path for the most cited articles about adverse drug events from 1987 to 2013 was as follows: detection, analysis, effect, and prevention from adult inpatient to pediatric inpatient settings and from hospitalized care to ambulatory care. In addition, social network analysis based on the most cited references revealed a close relationship between medication errors and adverse drug events. CONCLUSIONS The mapping results provide a valuable tool for researchers to access the literature in this field and can be used to help identify the direction of medication errors and adverse drug events research.
Collapse
|
13
|
Brown JD, Costales B, van Boemmel-Wegmann S, Goodin AJ, Segal R, Winterstein AG. Characteristics of Older Adults Who Were Early Adopters of Medical Cannabis in the Florida Medical Marijuana Use Registry. J Clin Med 2020; 9:E1166. [PMID: 32325769 PMCID: PMC7230351 DOI: 10.3390/jcm9041166] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Revised: 04/14/2020] [Accepted: 04/16/2020] [Indexed: 12/18/2022] Open
Abstract
Use of medical marijuana is increasing in the United States and older adults are the fastest growing user group. There is little information about the characteristics and outcomes related to medical marijuana use. This study is a descriptive analysis of older adults (aged ≥50 years old) who were early adopters of a medical marijuana program in the U.S. state of Florida. Per state legislation, initial and follow-up treatment plans were submitted to the University of Florida College of Pharmacy. Data collection included demographics, clinical history, medical conditions, substance use history, prescription history, and health status. Follow-up treatment plans noted changes in the chief complaint and actions taken since the initial visit. Of the state's 7548 registered users between August 2016 and July 2017, N = 4447 (58.9%) were older adults. Patients utilized cannabidiol (CBD)-only preparations (45%), preparations that had both tetrahydrocannabinol (THC) and CBD (33.3%) or were recorded to use both CBD-only and THC + CBD products (21.7%). The chief complaints indicating medical cannabis treatment were musculoskeletal disorders and spasms (48.4%) and chronic pain (45.4%). Among other prescription medications, patients utilized antidepressants (23.8%), anxiolytics and benzodiazepines (23.5%), opioids (28.6%), and cardiovascular agents (27.9%). Among all drug classes with potential sedating effects, 44.8% of the cohort were exposed to at least one. Patients with follow-up visits (27.5%) exhibited marked improvement as assessed by the authorizing physicians. However, the patient registry lacked detailed records and linkable information to other data resources to achieve complete follow up in order to assess safety or efficacy. Future improvements to registries are needed to more adequately capture patient information to fill knowledge gaps related to the safety and effectiveness of medical marijuana, particularly in the older adult population.
Collapse
Affiliation(s)
- Joshua D. Brown
- Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA; (B.C.); (S.v.B.-W.); (A.J.G.); (R.S.); (A.G.W.)
- Consortium for Medical Marijuana Clinical Outcomes Research, Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
| | - Brianna Costales
- Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA; (B.C.); (S.v.B.-W.); (A.J.G.); (R.S.); (A.G.W.)
| | - Sascha van Boemmel-Wegmann
- Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA; (B.C.); (S.v.B.-W.); (A.J.G.); (R.S.); (A.G.W.)
| | - Amie J. Goodin
- Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA; (B.C.); (S.v.B.-W.); (A.J.G.); (R.S.); (A.G.W.)
- Consortium for Medical Marijuana Clinical Outcomes Research, Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
| | - Richard Segal
- Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA; (B.C.); (S.v.B.-W.); (A.J.G.); (R.S.); (A.G.W.)
| | - Almut G. Winterstein
- Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA; (B.C.); (S.v.B.-W.); (A.J.G.); (R.S.); (A.G.W.)
- Consortium for Medical Marijuana Clinical Outcomes Research, Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
- Department of Epidemiology, University of Florida College of Colleges of Public Health and Health Professions and Medicine, Gainesville, FL 32610, USA
| |
Collapse
|
14
|
Schrader T, Tetzlaff L, Beck E, Mindt S, Geiss F, Hauser K, Franken C. [The similarity of drug names as a possible cause of confusion: Analysis of data from outpatient care]. ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN 2020; 150-152:29-37. [PMID: 32279980 DOI: 10.1016/j.zefq.2020.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/20/2019] [Revised: 01/24/2020] [Accepted: 01/28/2020] [Indexed: 11/20/2022]
Abstract
BACKGROUND The incidence of adverse drug events (ADE) described in the literature varies between 6.5 and 20 %. Furthermore, it is assumed that up to 29 % of ADE are due to medication errors as a result of confusion because of similarities in spelling (sound alike) or in name, physical appearance or packaging (look alike). Studies dealing with the so-called "LASA" issue were mostly carried out in inpatient care. As far as we know, no systematic investigations into this subject have been carried out for the outpatient sector where patients themselves take care of the application of their medication. In addition, there is no documentation about medication errors in the home setting. The aim of the present study is to describe the importance of the LASA issue in the home setting where medication errors are likely to occur due to similarity of drug names. METHODS In this context, the similarity of names of prescription drugs was systematically analyzed. We examined in detail how often prescription drug pairings showing orthographic and phonetic similarity were dispensed in the investigation period to an individual patient at the same time. Orthographic similarity was defined as relevant at a Levenshtein index value of ≤ 0.4. This corresponds to the similarity measures of the drugs listed in the LASA public lists and means that the similarity in the lettering of two drug names amounts to at least 60 %. Phonetic similarity was analysed using the Cologne Phonetic ("Kölner Phonetik") for the German language. RESULTS A total of 255,770 prescriptions were included in the analysis. In 11.4 %, drug pairings were detected that fall below the critical orthographic similarity threshold (Levenshtein index value ≤ 0.4), which represents an increased likelihood of medication error due to the critical similarity of drug names in this fraction. Within this group of "LASA drugs" different degrees of similarity were identified. Even drug pairings with very high orthographic similarity (Levenshtein index value from ≤ 0.1 and 0.1 to ≤ 0.2, 12.4 % and 3.6 % of the drug pairings, respectively) were detected. These drug pairings were mostly different in strength while active ingredients, manufacturer name and pharmaceutical form were the same. For the majority of drug pairings (84 %), the orthographic similarity was lower and showed a Levenshtein index value of ≥ 0.2 to 0.4. Despite different active ingredients, there is a degree of similarity resulting from both identical manufacturer name and pharmaceutical form appearing as part of the drug name. At the phonetic level, the analysis shows comparable frequency of similarity of drug pairings that are subject to potential medication error. DISCUSSION For the first time, a study was carried out in the outpatient setting recording the incidence of drug pairings that carry a risk for medication errors resulting from patients' confusion over too similar drug names. In the light of the age structure of the patients to whom these look- or sound-alike drugs are prescribed, we can assume that there is a considerable risk of ADE. The conceivable consequences of such medication errors on a pharmacological level range from relatively harmless to potentially highly dangerous. CONCLUSION There is a major need to fully inform patients about this risk of confusion and subsequent medication errors with certain drug combinations. The similarity structures of drug pairings identified in this study could serve as a basis for developing an appropriate information routine.
Collapse
Affiliation(s)
- Thomas Schrader
- Technische Hochschule Brandenburg, Fachbereich Informatik und Medien, Brandenburg, Deutschland
| | - Laura Tetzlaff
- Technische Hochschule Brandenburg, Fachbereich Informatik und Medien, Brandenburg, Deutschland.
| | - Eberhard Beck
- Technische Hochschule Brandenburg, Fachbereich Informatik und Medien, Brandenburg, Deutschland
| | | | | | | | | |
Collapse
|
15
|
Gates PJ, Baysari MT, Mumford V, Raban MZ, Westbrook JI. Standardising the Classification of Harm Associated with Medication Errors: The Harm Associated with Medication Error Classification (HAMEC). Drug Saf 2020; 42:931-939. [PMID: 31016678 PMCID: PMC6647434 DOI: 10.1007/s40264-019-00823-4] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Classifying harm associated with a medication error can be time consuming and labour intensive and limited studies undertake this step. There is no standardised process, and few studies that report harm assessment provide adequate methods to allow for study replication. Studies typically mention that a clinical review panel classified patient harm and provide a reference to a classification tool. Moreover, in many studies it is unclear whether potential or actual harm was classified as studies refer only to ‘error severity’. The tools used to categorise the severity of patient harm vary widely across studies and few have been assessed for inter-rater reliability and criterion validity. In this paper, we describe the systematic process we undertook to synthesise the defining elements and strengths, while mitigating the limitations, of existing harm classification tools to derive the Harm Associated with Medication Error Classification (HAMEC). This new tool provides a harm classification for use across clinical and research settings. The provision of an explicit process for its application and guiding category descriptors are designed to reduce the risk of misclassification and produce results that are comparable across studies. As the World Health Organisation embarks on its international safety challenge of reducing medication-related harm by 50%, accompanying methodological advances are required to measure progress.
Collapse
Affiliation(s)
- Peter J Gates
- Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia.
| | - Melissa T Baysari
- Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia
| | - Virginia Mumford
- Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia
| | - Magdalena Z Raban
- Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia
| | - Johanna I Westbrook
- Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia
| |
Collapse
|
16
|
Patel E, Pevnick JM, Kennelty KA. Pharmacists and medication reconciliation: a review of recent literature. INTEGRATED PHARMACY RESEARCH AND PRACTICE 2019; 8:39-45. [PMID: 31119096 PMCID: PMC6500442 DOI: 10.2147/iprp.s169727] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2018] [Accepted: 02/28/2019] [Indexed: 11/23/2022] Open
Abstract
Background: Adverse drug event (ADE) errors are common and costly in health care systems across the world. Medication reconciliation is a means to decrease these medication-related injuries and increase quality of care. Research has shown that medication reconciliation accuracy and efficiency improved when pharmacists are directly involved in the process. Objective: We review studies examining how pharmacists impact the medication reconciliation process and we discuss pharmacists' future roles during the medication reconciliation process and then barriers pharmacy staff may face during this critical process. Methods: A comprehensive literature search from MEDLINE and manual searching of bibliographies was performed for the time period January 2012 through November 2018. Conclusion: Although the issue of rising costs and injury due to medication errors in our health care system are not solvable via medication reconciliation alone, it is the first and perhaps most critical piece of the medication management puzzle. As such, numerous organizations have called for pharmacists to expand their roles in the medication reconciliation process due to their expertise in medication management.
Collapse
Affiliation(s)
- Eesha Patel
- Department of Pharmacy and Practice, Division of Health Services Research, University of Iowa, Iowa City, IA, USA
| | - Joshua M Pevnick
- Department of Medicine, Division of General Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- Department of Biomedical Sciences, Division of Informatics, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Korey A Kennelty
- Department of Pharmacy and Practice, Division of Health Services Research, University of Iowa, Iowa City, IA, USA
| |
Collapse
|
17
|
|
18
|
Bhavsar GP, Probst JC, Bennett KJ, Hardin JW, Qureshi Z. Community-level electronic prescribing and adverse drug event hospitalizations among older adults. Health Informatics J 2017; 25:661-675. [PMID: 28737062 DOI: 10.1177/1460458217720396] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
This study sought to determine how the proportion of physicians using electronic prescribing in nine US states was associated with the hospitalization rate for adverse drug events among older adult patients. A discharge-level analysis of the relationship between county electronic prescribing and adverse drug event hospitalization rates was conducted. Data from the 2011 State Inpatient Databases, the Office of the National Coordinator Health IT Dashboard, and the Area Health Resource File were obtained for nine US states. The analysis examined the odds that a discharge for older adults would have been adverse drug event associated, versus other causes, using multivariable logistic regression models. After adjusting for patient, provider, health infrastructure, and community factors, the lowest county electronic prescribing rate quartile was associated with significantly greater odds of an adverse drug event hospitalization (odds ratio: 1.10; 95% confidence interval: 1.02-1.19). Early results indicate greater odds of adverse drug event hospitalizations among older adults living in counties with low electronic prescribing rates when compared to those in high electronic prescribing counties.
Collapse
|
19
|
Marquet K, Claes N, De Troy E, Kox G, Droogmans M, Vleugels A. A multicenter record review of in-hospital adverse drug events requiring a higher level of care. Acta Clin Belg 2017; 72:156-162. [PMID: 28156198 DOI: 10.1080/17843286.2017.1283759] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
OBJECTIVE Adverse drug events (ADEs) are a worldwide concern, particularly when leading to a higher level of care. This study defines a higher level of care as an unplanned (re)admission to an intensive care unit or an intervention by a Medical Emergency Team. The objectives are to describe the incidence and preventability of ADEs leading to a higher level of care, to assess the types of drug involved, and to identify the risk factors. METHODS A three-stage retrospective review was performed in six Belgian hospitals. Patient records were assessed by a trained clinical team consisting of a nurse, a physician, and a clinical pharmacist. Descriptive statistics, univariate, and multiple logistic regressions were used. RESULTS In this study, 830 patients were detected for whom a higher level of care had been needed. In 160 (19.3%) cases, an ADE had occurred; 134 (83.8%) of these were categorized as preventable adverse drug events (pADEs). The overall incidence rate of patients transferred to a higher level of care because of a pADE was 33.9 (95% CI: 28.5-39.3) per 100,000 patient days at risk. Antibiotics and antithrombotic agents accounted both for one-fifth of all pADEs. Multivariate analysis indicated American Society of Anaesthesiologists physical status score as a risk factor for pADEs. CONCLUSIONS The high number of pADE with patient harm shows that there is a need for structural improvement of pharmacotherapeutic care. Detection of these pADEs can be the basis for the implementation of these improvements.
Collapse
Affiliation(s)
- Kristel Marquet
- Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium
- Jessa Hospital, Hasselt, Belgium
| | - Neree Claes
- Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium
- Health Care Management, Antwerp Management School, Antwerp, Belgium
| | - Elke De Troy
- Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium
- Jessa Hospital, Hasselt, Belgium
| | - Gaby Kox
- Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium
| | - Martijn Droogmans
- Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium
- Jessa Hospital, Hasselt, Belgium
| | - Arthur Vleugels
- Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium
- Centre for Health Services and Nursing Research, Catholic University Leuven, Leuven, Belgium
| |
Collapse
|
20
|
Hutton B, Kanji S, McDonald E, Yazdi F, Wolfe D, Thavorn K, Pepper S, Chapman L, Skidmore B, Moher D. Incidence, causes, and consequences of preventable adverse drug events: protocol for an overview of reviews. Syst Rev 2016; 5:209. [PMID: 27919281 PMCID: PMC5139092 DOI: 10.1186/s13643-016-0392-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/24/2016] [Accepted: 11/26/2016] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Medication errors represent a noteworthy source of harm to patients. In recent years, several systematic reviews have assessed the frequency and causes of these events, as well as other factors such as commonly associated drugs, their incidence in different specialties, and their consequences to patients. Despite this past literature, there remains a need to study discrepancies between these reviews and establish the current state of the evidence. The planned review will bring together, compare, and contract existing evidence related to the occurrence of medication errors in acute and continuing/long-term care settings. METHODS A systematic review of reviews will be performed. A literature search designed by an experienced information specialist will be carried out in Medline, Embase, and the Cochrane Library. We will seek systematic reviews and meta-analyses of primary research studies that evaluate one or more of the following aspects of the occurrence of preventable adverse drug events in hospitals and long-term care centers: the incidence of preventable adverse drug events, either overall or within subgroups of interest related to setting; drug or patient characteristics; cited consequences of these events to patients, including death, emergency room visits, or other outcomes; and established causes of the preventable adverse drug events. Two researchers will independently screen all abstracts and full texts for study selection and subsequently perform data extraction from all included studies. Quality of the reviews will be assessed using the assessing the methodological quality of systematic reviews (AMSTAR) tool. Where objectives from two or more reviews overlap, we will employ the Jadad framework to assess the causes of any noted discrepancies between reviews. An overall summary of results will be performed using tabular and graphical approaches and will be supplemented by narrative description. DISCUSSION This overview will help synthesize the broad degree of information available on this important topic. This review is being performed by members of the Drug Safety and Effectiveness Network along with collaboration from Health Canada, and its findings will be published in a peer-reviewed journal. The results may also inform future research in this area. SYSTEMATIC REVIEW REGISTRATION PROSPERO CRD42016043220.
Collapse
Affiliation(s)
- Brian Hutton
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6 Canada
- School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, Canada
| | - Salmaan Kanji
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6 Canada
- The Ottawa Hospital, Ottawa, Canada
| | - Erika McDonald
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6 Canada
- The Ottawa Hospital, Ottawa, Canada
| | - Fatemeh Yazdi
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6 Canada
| | - Dianna Wolfe
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6 Canada
| | - Kednapa Thavorn
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6 Canada
- School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, Canada
- Institute of Clinical and Evaluative Sciences (ICES uOttawa), Ottawa, Canada
| | - Sally Pepper
- Health Canada, Marketed Health Products Directorate, Ottawa, Canada
| | - Laurie Chapman
- Health Canada, Marketed Health Products Directorate, Ottawa, Canada
| | - Becky Skidmore
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6 Canada
| | - David Moher
- Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6 Canada
- School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, Canada
| |
Collapse
|
21
|
Fleury MJ, Djouini A, Huỳnh C, Tremblay J, Ferland F, Ménard JM, Belleville G. Remission from substance use disorders: A systematic review and meta-analysis. Drug Alcohol Depend 2016; 168:293-306. [PMID: 27614380 DOI: 10.1016/j.drugalcdep.2016.08.625] [Citation(s) in RCA: 97] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2016] [Revised: 08/22/2016] [Accepted: 08/23/2016] [Indexed: 10/21/2022]
Abstract
OBJECTIVE This paper presents a systematic review and meta-analysis of available evidence on remission rates for substance use disorders (SUDs), providing weighted mean estimates of SUD remission rates. The review also explores study-level characteristics that may explain variations in remission rates across studies. METHODS A comprehensive search strategy identified studies published between 2000 and 2015 with follow-up periods of at least three years or reported lifetime remission outcomes for potential inclusion in the review. Remission was defined as not meeting diagnostic criteria for abuse or dependence for a minimum period of six months, as of final follow-up. A single-group summary meta-analysis was performed. Pooled estimated annual remission rates (PEARRs) were calculated. Meta-regression techniques and subgroup analyses were used to explore the association between study remission rates and key selected variables. RESULTS Of 8855 studies identified, 21 met the eligibility criteria. The results suggested that 35.0% to 54.4% of individuals with SUDs achieved remission, and this occurred after a mean follow-up period of 17 years. The PEARRs projected few cases of SUD remission, between 6.8% and 9.1% in any given year. Studies that reported higher remission rates had longer follow-up periods, and lower sample retention rates. CONCLUSIONS Results support the contention that SUDs are more likely to be "chronic" or long term disorders than acute disorders for a substantial number of individuals. However, more longitudinal research is required. Treatment geared to chronicity, such as assertive community treatment and intensive case management, needs to be more readily available for SUD populations.
Collapse
Affiliation(s)
- M-J Fleury
- Department of Psychiatry, McGill University, Montreal, Canada.
| | - Akram Djouini
- Centre de recherche et d'expertise en dépendance du Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Centre-Sud-de-l'Île-de-Montréal (Addiction Rehabilitation Center-University Institute), Montreal, Canada.
| | - Christophe Huỳnh
- Centre de recherche et d'expertise en dépendance du Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Centre-Sud-de-l'Île-de-Montréal (Addiction Rehabilitation Center-University Institute), Montreal, Canada.
| | - Joël Tremblay
- Department of Psycho-education, Université du Québec à Trois-Rivières, Trois-Rivières, Canada.
| | - Francine Ferland
- Centre de réadaptation en dépendance du CIUSSS de la Capitale-Nationale (Addiction Rehabilitation Center), Université Laval, Québec, Canada.
| | - J-M Ménard
- CIUSSS de-la-Mauricie-et-du-Centre-du-Québec (Addiction Rehabilitation Center), Trois-Rivières, Canada.
| | | |
Collapse
|
22
|
Danino J, Muzaffar J, Metcalfe C, Coulson C. Patient safety in otolaryngology: a descriptive review. Eur Arch Otorhinolaryngol 2016; 274:1317-1326. [PMID: 27623822 DOI: 10.1007/s00405-016-4291-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Accepted: 08/31/2016] [Indexed: 11/30/2022]
Abstract
Human evaluation and judgement may include errors that can have disastrous results. Within medicine and healthcare there has been slow progress towards major changes in safety. Healthcare lags behind other specialised industries, such as aviation and nuclear power, where there have been significant improvements in overall safety, especially in reducing risk of errors. Following several high profile cases in the USA during the 1990s, a report titled "To Err Is Human: Building a Safer Health System" was published. The report extrapolated that in the USA approximately 50,000 to 100,000 patients may die each year as a result of medical errors. Traditionally otolaryngology has always been regarded as a "safe specialty". A study in the USA in 2004 inferred that there may be 2600 cases of major morbidity and 165 deaths within the specialty. MEDLINE via PubMed interface was searched for English language articles published between 2000 and 2012. Each combined two or three of the keywords noted earlier. Limitations are related to several generic topics within patient safety in otolaryngology. Other areas covered have been current relevant topics due to recent interest or new advances in technology. There has been a heightened awareness within the healthcare community of patient safety; it has become a major priority. Focus has shifted from apportioning blame to prevention of the errors and implementation of patient safety mechanisms in healthcare delivery. Type of Errors can be divided into errors due to action and errors due to knowledge or planning. In healthcare there are several factors that may influence adverse events and patient safety. Although technology may improve patient safety, it also introduces new sources of error. The ability to work with people allows for the increase in safety netting. Team working has been shown to have a beneficial effect on patient safety. Any field of work involving human decision-making will always have a risk of error. Within Otolaryngology, although patient safety has evolved along similar themes as other surgical specialties; there are several specific high-risk areas. Medical error is a common problem and its human cost is of immense importance. Steps to reduce such errors require the identification of high-risk practice within a complex healthcare system. The commitment to patient safety and quality improvement in medicine depend on personal responsibility and professional accountability.
Collapse
Affiliation(s)
- Julian Danino
- Queen Elizabeth Hospital Birmingham, Birmingham, B15 2TH, England, UK.
| | - Jameel Muzaffar
- Queen Elizabeth Hospital Birmingham, Birmingham, B15 2TH, England, UK
| | - Chris Metcalfe
- Queen Elizabeth Hospital Birmingham, Birmingham, B15 2TH, England, UK
| | - Chris Coulson
- Queen Elizabeth Hospital Birmingham, Birmingham, B15 2TH, England, UK
| |
Collapse
|
23
|
Rochoy M, Béné J, Messaadi N, Auffret M, Gautier S. Évaluation du site internet du centre régional de pharmacovigilance du Nord-Pas-de-Calais. Therapie 2016; 71:329-33. [DOI: 10.1016/j.therap.2015.10.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2015] [Accepted: 10/08/2015] [Indexed: 11/16/2022]
|
24
|
Rochoy M, Gautier S, Bordet R, Caron J, Launay D, Hachulla E, Hatron PY, Lambert M. Interactions pharmacovigilance – service de médecine interne : une aide précieuse au diagnostic. Rev Med Interne 2015; 36:516-21. [DOI: 10.1016/j.revmed.2015.02.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2014] [Revised: 12/28/2014] [Accepted: 02/07/2015] [Indexed: 10/23/2022]
|
25
|
Hecht T, Bundscherer AC, Lassen CL, Lindenberg N, Graf BM, Ittner KP, Wiese CHR. The expenditure of computer-related worktime using clinical decision support systems in chronic pain therapy. BMC Anesthesiol 2015; 15:113. [PMID: 26231078 PMCID: PMC4521352 DOI: 10.1186/s12871-015-0094-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Accepted: 07/16/2015] [Indexed: 02/03/2023] Open
Abstract
Background Estimate the expenditure of computer-related worktime resulting from the use of clinical decision support systems (CDSS) to prevent adverse drug reactions (ADR) among patients undergoing chronic pain therapy and compare the employed check systems with respect to performance and practicability. Methods Data were collected retrospectively from 113 medical records of patients under chronic pain therapy during 2012/2013. Patient-specific medications were checked for potential drug-drug interactions (DDI) using two publicly available CDSS, Apotheken Umschau (AU) and Medscape (MS), and a commercially available CDSS AiDKlinik® (AID). The time needed to analyze patient pharmacotherapy for DDIs was taken with a stopwatch. Measurements included the time needed for running the analysis and printing the results. CDSS were compared with respect to the expenditure of time and usability. Only patient pharmacotherapies with at least two prescribed drugs and fitting the criteria of the corresponding CDSS were analyzed. Additionally, a qualitative evaluation of the used check systems was performed, employing a questionnaire asking five pain physicians to compare and rate the performance and practicability of the three CDSSs. Results The AU tool took a total of 3:55:45 h with an average of 0:02:32 h for 93 analyzed patient regimens and led to the discovery of 261 DDIs. Using the Medscape interaction checker required a total of 1:28:35 h for 38 patients with an average of 0:01:58 h and a yield of 178 interactions. The CDSS AID required a total of 3:12:27 h for 97 patients with an average time of analysis of 0:01:59 h and the discovery of 170 DDIs. According to the pain physicians the CDSS AID was chosen as the preferred tool. Conclusions Applying a CDSS to examine a patients drug regimen for potential DDIs causes an average extra expenditure of work time of 2:09 min, which extends patient treatment time by 25 % on average. Nevertheless, the authors believe that the extra expenditure of time employing a CDSS is outweighed by their benefits, including reduced ADR risks and safer clinical drug management.
Collapse
Affiliation(s)
- Timm Hecht
- Department of Anesthesiology, University Medical Centre Regensburg, Franz-Josef-Strauß-Allee 11, D-93053, Regensburg, Germany
| | - Anika C Bundscherer
- Department of Anesthesiology, University Medical Centre Regensburg, Franz-Josef-Strauß-Allee 11, D-93053, Regensburg, Germany
| | - Christoph L Lassen
- Department of Anesthesiology, University Medical Centre Regensburg, Franz-Josef-Strauß-Allee 11, D-93053, Regensburg, Germany
| | - Nicole Lindenberg
- Department of Anesthesiology, University Medical Centre Regensburg, Franz-Josef-Strauß-Allee 11, D-93053, Regensburg, Germany.
| | - Bernhard M Graf
- Department of Anesthesiology, University Medical Centre Regensburg, Franz-Josef-Strauß-Allee 11, D-93053, Regensburg, Germany
| | - Karl-Peter Ittner
- Department of Anesthesiology, University Medical Centre Regensburg, Franz-Josef-Strauß-Allee 11, D-93053, Regensburg, Germany
| | - Christoph H R Wiese
- Department of Anesthesiology, University Medical Centre Regensburg, Franz-Josef-Strauß-Allee 11, D-93053, Regensburg, Germany.
| |
Collapse
|
26
|
Abstract
Pharmacovigilance (PV) plays a key role in the healthcare system through
assessment, monitoring and discovery of interactions amongst drugs and their
effects in human. Pharmaceutical and biotechnological medicines are designed to
cure, prevent or treat diseases; however, there are also risks particularly
adverse drug reactions (ADRs) can cause serious harm to patients. Thus, for
safety medication ADRs monitoring required for each medicine throughout its life
cycle, during development of drug such as pre-marketing including early stages
of drug design, clinical trials, and post-marketing surveillance. PV is concerns
with the detection, assessment, understanding and prevention of ADRs.
Pharmacogenetics and pharmacogenomics are an indispensable part of the clinical
research. Variation in the human genome is a cause of variable response to drugs
and susceptibility to diseases are determined, which is important for early drug
discovery to PV. Moreover, PV has traditionally involved in mining spontaneous
reports submitted to national surveillance systems. The research focus is
shifting toward the use of data generated from platforms outside the
conventional framework such as electronic medical records, biomedical
literature, and patient-reported data in health forums. The emerging trend in PV
is to link premarketing data with human safety information observed in the
post-marketing phase. The PV system team obtains valuable additional
information, building up the scientific data contained in the original report
and making it more informative. This necessitates an utmost requirement for
effective regulations of the drug approval process and conscious pre and post
approval vigilance of the undesired effects, especially in India. Adverse events
reported by PV system potentially benefit to the community due to their
proximity to both population and public health practitioners, in terms of
language and knowledge, enables easy contact with reporters by electronically.
Hence, PV helps to the patients get well and to manage optimally or ideally,
avoid illness is a collective responsibility of industry, drug regulators,
clinicians and other healthcare professionals to enhance their contribution to
public health. This review summarized objectives and methodologies used in PV
with critical overview of existing PV in India, challenges to overcome and
future prospects with respect to Indian context.
Collapse
|
27
|
Kelishadi R, Mousavinasab F. Rational use of medicine in the pediatric age group: A summary on the role of clinical pharmacists. J Res Pharm Pract 2014; 1:10-3. [PMID: 24991581 PMCID: PMC4076854 DOI: 10.4103/2279-042x.99671] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Medication errors (ME) and adverse drug reactions still continue to be the important factors for out- and in-patient treatments. MEs are critical troubles in all hospitalized populations that can increase length of hospital stay, expenses, mortality and morbidity. In many countries, clinical pharmacists have been involved in reducing MEs from years ago. A growing body of evidence suggests that pharmacist interventions have major impact on reducing MEs in pediatric patients, thus improving the quality and efficiency of care provided. This paper presents a literature review on the role of clinical pharmacists in reducing MEs, and underscores the importance of pharmacist-physician-patient collaboration for all patients notably in the pediatric age group.
Collapse
Affiliation(s)
- Roya Kelishadi
- Pediatrics Department, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Firoozeh Mousavinasab
- Pediatrics Department, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
28
|
Buck TC, Gronkjaer LS, Duckert ML, Rosholm JU, Aagaard L. Medication reconciliation and prescribing reviews by pharmacy technicians in a geriatric ward. J Res Pharm Pract 2014; 2:145-50. [PMID: 24991623 PMCID: PMC4076929 DOI: 10.4103/2279-042x.128143] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
OBJECTIVE Incomplete medication histories obtained on hospital admission are responsible for more than 25% of prescribing errors. This study aimed to evaluate whether pharmacy technicians can assist hospital physicians' in obtaining medication histories by performing medication reconciliation and prescribing reviews. A secondary aim was to evaluate whether the interventions made by pharmacy technicians could reduce the time spent by the nurses on administration of medications to the patients. METHODS This observational study was conducted over a 7 week period in the geriatric ward at Odense University Hospital, Denmark. Two pharmacy technicians conducted medication reconciliation and prescribing reviews at the time of patients' admission to the ward. The reviews were conducted according to standard operating procedures developed by a clinical pharmacist and approved by the Head of the Geriatric Department. FINDINGS In total, 629 discrepancies were detected during the conducted medication reconciliations, in average 3 for each patient. About 45% of the prescribing discrepancies were accepted and corrected by the physicians. "Medication omission" was the most frequently detected discrepancy (46% of total). During the prescribing reviews, a total of 860 prescription errors were detected, approximately one per medication review. Almost all of the detected prescription errors were later accepted and/or corrected by the physicians. "Dosage and time interval errors" were the most frequently detected error (48% of total). The time used by nurses for administration of medicines was reduced in the study period. CONCLUSION This study suggests that pharmacy technicians can contribute to a substantial reduction in medication discrepancies in acutely admitted patients by performing medication reconciliation and focused medication reviews. Further randomized, controlled studies including a larger number of patients are required to elucidate whether these observations are of significance and of importance for securing patient safety.
Collapse
Affiliation(s)
- Thomas Croft Buck
- Department of Clinical Pharmacy, Odense University Hospital Pharmacy, Odense, Denmark ; Department of Clinical Pharmacy, Hospitals Unit for Quality Assurance of Medicines Use, Odense University Hospital, Odense, Denmark
| | - Louise Smed Gronkjaer
- Department of Clinical Pharmacy, Odense University Hospital Pharmacy, Odense, Denmark ; Department of Clinical Pharmacy, Hospitals Unit for Quality Assurance of Medicines Use, Odense University Hospital, Odense, Denmark
| | - Marie-Louise Duckert
- Department of Clinical Pharmacy, Odense University Hospital Pharmacy, Odense, Denmark ; Department of Clinical Pharmacy, Hospitals Unit for Quality Assurance of Medicines Use, Odense University Hospital, Odense, Denmark
| | - Jens-Ulrik Rosholm
- Department of Geriatric Medicine, Odense University Hospital, Odense, Denmark
| | - Lise Aagaard
- Department of Clinical Pharmacy, Hospitals Unit for Quality Assurance of Medicines Use, Odense University Hospital, Odense, Denmark ; Clinical pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark
| |
Collapse
|
29
|
|
30
|
Meier F, Maas R, Sonst A, Patapovas A, Müller F, Plank-Kiegele B, Pfistermeister B, Schöffski O, Bürkle T, Dormann H. Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiol Drug Saf 2014; 24:176-86. [PMID: 24934134 DOI: 10.1002/pds.3663] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2012] [Revised: 05/12/2014] [Accepted: 05/14/2014] [Indexed: 11/09/2022]
Abstract
PURPOSE Several economic evaluations of adverse drug events (ADEs) exist, but the underlying methodology has not been standardized so far. The aim of the study was to combine prospective, intensive pharmacovigilance methods, and standardized accounting data to calculate direct costs of community-acquired ADEs (caADEs) contributing to emergency department (ED) admission and subsequent hospitalization. METHODS A prospective observational study with three phases extending over 2 years was implemented in a 749 bed tertiary care hospital with an annual ED census of approximately 45 000 patients. The patient records of all adult non-trauma ED admissions were systematically analyzed by a team of emergency physicians, clinical pharmacologists, and pharmacists for potential ADE. Associated diagnosis related group costs were extracted from standardized accounting data. RESULTS Of 2262 patients attending the ED during the study periods, the hospitalization of 366 patients (16.2%) was related to one or more caADEs of which 97.5% were considered predictable and 62.0% were classified as preventable. The mean caADE-related diagnosis related group costs were €2743 (95% bias-corrected and accelerated CI: €2498 to €3018). Extrapolated to a national scale, this corresponds to caADE-related costs of €2.245bn for the German health insurance funds, annually. Costs of €1.310bn could be attributed to events classified as predictable and preventable. CONCLUSIONS In an ED, caADEs are frequent, and a significant proportion of these events and their related costs appear to be predictable and preventable. The ED as a first-line provider for ADE cases appears to be an appropriate environment to implement strategic and operative improvements for enhanced patient safety.
Collapse
Affiliation(s)
- Florian Meier
- Department of Health Management, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nuremberg, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Ammenwerth E, Aly AF, Bürkle T, Christ P, Dormann H, Friesdorf W, Haas C, Haefeli WE, Jeske M, Kaltschmidt J, Menges K, Möller H, Neubert A, Rascher W, Reichert H, Schuler J, Schreier G, Schulz S, Seidling HM, Stühlinger W, Criegee-Rieck M. Memorandum on the use of information technology to improve medication safety. Methods Inf Med 2014; 53:336-43. [PMID: 24902537 DOI: 10.3414/me14-01-0040] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2014] [Accepted: 05/01/2014] [Indexed: 12/12/2022]
Abstract
BACKGROUND Information technology in health care has a clear potential to improve the quality and efficiency of health care, especially in the area of medication processes. On the other hand, existing studies show possible adverse effects on patient safety when IT for medication-related processes is developed, introduced or used inappropriately. OBJECTIVES To summarize definitions and observations on IT usage in pharmacotherapy and to derive recommendations and future research priorities for decision makers and domain experts. METHODS This memorandum was developed in a consensus-based iterative process that included workshops and e-mail discussions among 21 experts coordinated by the Drug Information Systems Working Group of the German Society for Medical Informatics, Biometry and Epidemiology (GMDS). RESULTS The recommendations address, among other things, a stepwise and comprehensive strategy for IT usage in medication processes, the integration of contextual information for alert generation, the involvement of patients, the semantic integration of information resources, usability and adaptability of IT solutions, and the need for their continuous evaluation. CONCLUSION Information technology can help to improve medication safety. However, challenges remain regarding access to information, quality of information, and measurable benefits.
Collapse
Affiliation(s)
- E Ammenwerth
- Elske Ammenwerth, Institute of Health Informatics, University for Health Sciences, Medical Informatics and Technology (UMIT), Eduard Wallnöfer-Zentrum 1, 6060 Hall in Tirol, Austria, E-mail:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Maaskant JM, Eskes A, van Rijn-Bikker P, Bosman D, van Aalderen W, Vermeulen H. High-alert medications for pediatric patients: an international modified Delphi study. Expert Opin Drug Saf 2013; 12:805-14. [PMID: 23931332 DOI: 10.1517/14740338.2013.825247] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND The available knowledge about high-alert medications for children is limited. Because children are particularly vulnerable to medication errors, a list of high-alert medication specifically for children would help to develop effective strategies to prevent patient harm. Therefore, we conducted an international modified Delphi study and validated the results with reports on medication incidents in children based on national data. OBJECTIVE The objective of this study was to generate an internationally accepted list of high-alert medications for a pediatric inpatient population from birth to 18-years old. RESULTS The rating panel consisted of 34 experts from 13 countries. In total, 14 medications and 4 medication classes were included with the predefined level of consensus of 75%. The high-alert medications were: amiodarone, digoxin, dopamine, epinephrine, fentanyl, gentamycin, heparine, insulin, morphine, norepinephrine, phenytoin, potassium, propofol and tacrolimus. The high-alert medication classes included in the final list were: chemotherapeutic drugs, immunosuppressive medications, lipid/total parenteral nutrition and opioids. CONCLUSION An international group of experts defined 14 medications and 4 medication classes as high-alert for children. This list might be helpful as a starting point for individual hospitals to develop their own high-alert list tailored to their unique situation.
Collapse
Affiliation(s)
- Jolanda M Maaskant
- Emma Children's Hospital, Academic Medical Center , PO Box 22660, 1100 DE Amsterdam , the Netherlands +31205668173 ; +31206917735 ;
| | | | | | | | | | | |
Collapse
|
33
|
Bruno CB, Ip E, Shah B, Linn WD. A mnemonic for pharmacy students to use in pharmacotherapy assessment. AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION 2012; 76:16. [PMID: 22412215 PMCID: PMC3298398 DOI: 10.5688/ajpe76116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/18/2011] [Accepted: 09/01/2011] [Indexed: 05/31/2023]
Abstract
OBJECTIVE To introduce pharmacy students to a patient-centered mnemonic to aid them in remembering the most important parameters when assessing a patient's drug therapy and to determine whether use of the device improved students' clinical examination scores. DESIGN Second-year pharmacy students were randomized to an intervention group or a control group. A 30-minute presentation on the rationale of the mnemonic and how to apply it to clinical scenarios was given to the intervention group and then a case-based multiple-choice clinical examination was administered. Students in the control group completed the same examination first and then were given the mnemonic. ASSESSMENT Ninety-five students completed the examination. Examination scores of students in the intervention group were 6% higher than those of students in the control group (p = 0.04). A 6-question survey instrument was administered to both groups and the majority of students agreed that they would use the mnemonic when assessing patients during their upcoming practice experiences. One-hundred percent of the students stated that the mnemonic definitely or probably helped them (or would have helped them) think critically when assessing the patient cases. CONCLUSIONS Pharmacy students who used a mnemonic device for pharmacotherapy assessment exhibited better decision-making skills and made fewer errors than students who did not use the mnemonic.
Collapse
|
34
|
Preyde M, Brassard K. Evidence-based risk factors for adverse health outcomes in older patients after discharge home and assessment tools: a systematic review. JOURNAL OF EVIDENCE-BASED SOCIAL WORK 2011; 8:445-468. [PMID: 22035470 DOI: 10.1080/15433714.2011.542330] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
The current health care system is discharging elderly patients "quicker" and "sicker" from acute care facilities. Consequently, hospital readmission is common; however, readmission may be only one aspect of adverse outcomes of importance to social work discharge planners. The early recognition of risk factors might ensure a successful transition from the hospital to the home. A systematic review was conducted to identify factors associated with adverse outcomes in older patients discharged from hospital to home. Using a content analysis, factors were characterized in five domains: demographic factors, patient characteristics, medical and biological factors, social factors, and discharge factors. The most frequently reported risks were depression, poor cognition, comorbidities, length of hospital stay, prior hospital admission, functional status, patient age, multiple medications, and lack of social support. A systematic search identified four discharge assessment tools for use with the general population of elderly patients. Practice and research implications are offered.
Collapse
Affiliation(s)
- Michèle Preyde
- Department of Family Relations and Applied Nutrition, University of Guelph, Guelph, Ontario, Canada.
| | | |
Collapse
|
35
|
Lua HL, Sklar G, Ko Y. Identification and physicians' views of their commonly-used drug information sources in Singapore. Int J Clin Pharm 2011; 33:772-8. [PMID: 21739225 DOI: 10.1007/s11096-011-9533-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2010] [Accepted: 06/13/2011] [Indexed: 10/18/2022]
Abstract
AIM To examine physicians' use and views of various sources for general drug information and to determine the kind of drug-related questions they receive. METHOD An online survey of general practitioners who were Singapore Medical Association members was conducted. The survey consisted of questions about the physicians' demographics, the drug information source they used most often, their opinions on the information from that source, and the types of drug-related questions they received from patients. RESULTS Among the 236 physicians who responded to the survey, 58.1% used reference texts most frequently; of these respondents, 80.3% used the Monthly Index of Medical Specialties. Only 4.2% most often go to pharmacists for drug information. Of the 75 (31.8%) respondents who chose online sources, about half used Google while the remainder used specific websites. Most respondents rated drug information from reference texts as somewhat comprehensive (71.5%) and usually reliable (81.8%). The choice of drug information sources was associated with physicians' age, place of practice, access to the Internet, and clinical experience (P < 0.05). The types of drug-related questions that physicians most frequently received were with regards to adverse drug reactions (76.3%), drug costs (36.4%), and drug use during pregnancy or lactation (34.3%). CONCLUSION Most physicians in Singapore search for general drug information using reference texts and consider them to be comprehensive and reliable. Questions pertaining to adverse drug reactions were the drug-related questions physicians most frequently receive. It is important for physicians to have appropriate drug information references and learn methods with which to verify the credibility of drug information obtained from the Internet. Pharmacists can also work to improve their role as providers of drug information.
Collapse
|
36
|
Riedmann D, Jung M, Hackl WO, Ammenwerth E. How to improve the delivery of medication alerts within computerized physician order entry systems: an international Delphi study. J Am Med Inform Assoc 2011; 18:760-6. [PMID: 21697293 DOI: 10.1136/amiajnl-2010-000006] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
OBJECTIVES To determine what information can be helpful in prioritizing and presenting medication alerts according to the context of the clinical situation. To assess the usefulness of different ways of delivering medication alerts to the user. DESIGN An international Delphi study with two quantitative rounds. 69 researchers with expertise in computerized physician order entry (CPOE) systems were asked to estimate the usefulness of 20 possible context factors, and to assess the potential impact of six innovative ways of delivering alert information on adverse drug event (ADE) rates. RESULTS Participants identified the following top five context information items (in descending order of usefulness): (1) severity of the effect of the ADE the alert refers to; (2) clinical status of the patient; (3) probability of occurrence of the ADE the alert refers to; (4) risk factors of the patient; and (5) strength of evidence on which the alert is built. The ways of delivering alert information with the highest estimated ADE reduction potential are active alerting, proactive prescription simulation and a patient medication module that gives patient-oriented alert information. LIMITATIONS Most participants had a research-oriented focus; therefore the results may not reflect the opinions of CPOE users or CPOE implementers. CONCLUSION The study results may provide CPOE system developers and healthcare institutions with information on how to design more effective alert mechanisms.
Collapse
Affiliation(s)
- Daniel Riedmann
- Institute for Medical Informatics, UMIT-University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria
| | | | | | | |
Collapse
|
37
|
Meyer-Massetti C, Cheng CM, Schwappach DLB, Paulsen L, Ide B, Meier CR, Guglielmo BJ. Systematic review of medication safety assessment methods. Am J Health Syst Pharm 2011; 68:227-40. [DOI: 10.2146/ajhp100019] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
- Carla Meyer-Massetti
- Medication Safety And Drug Event Monitoring, Swiss Patient Safety Foundation (SPSF), Zurich, Switzerland, and Junior Specialist, Medication Outcomes Center, Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco (UCSF), San Francisco
| | - Christine M. Cheng
- Medication Outcomes Center, Department of Clinical Pharmacy, School of Pharmacy, UCSF
| | - David L. B. Schwappach
- Division of Social and Behavioral Health Research, Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
| | | | - Brigid Ide
- Patient Safety and Quality Services, UCSF Medical Center
| | - Christoph R. Meier
- Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland, and Director of Pharmaceutical Services, Hospital Pharmacy, University Hospital Basel, Basel
| | | |
Collapse
|
38
|
Abstract
BACKGROUND Medication prescribing is a complex process where the focus tends to be on starting new medication, changing a drug regimen, and continuing a drug regimen. On occasion, a prudent approach to prescribing may necessitate ending an ongoing course of medication, either because it should not have been started in the first place; because its continued use would cause harm; or because the medication is no longer effective. OBJECTIVE To identify effective strategies for stopping pre-existing prescribing in situations where continued prescribing may no longer be clinically warranted. RESEARCH DESIGN Systematic searches for English-language reports of experimental and quasi-experimental research were conducted in PubMed (1951-November 2009), EMBASE (1966-September 2008), and International Pharmaceutical Abstract b (1970-September 2008). A manual search for relevant review articles and a keyword search of a local database produced by a previous systematic search for prescribing influence and intervention research were also conducted. STUDY SELECTION AND DATA EXTRACTION Following initial title screening for relevance 2 reviewers, using formal assessment and data extraction tools, independently assessed abstracts for relevance and full studies for quality before extracting data from studies selected for inclusion. RESULTS Of 1306 articles reviewed, 12 were assessed to be of relevant, high-quality research. A variety of drugs were examined in the included studies with benzodiazepines the most common. Studies included in the review tested 9 different types of interventions. Effective interventions included patient-mediated interventions, manual reminders to prescribers, educational materials given to patients, a face-to-face intervention with prescribers, and a case of regulatory intervention. Partially effective interventions included audit and feedback, electronic reminders, educational materials alone sent to prescribers, and distance communication combined with educational materials sent to prescribers. CONCLUSIONS It appears possible to stop the prescribing of a variety of medications with a range of interventions. A common theme in effective interventions is the involvement of patients in the stopping process. However, prescribing at the level of individual patients was rarely reported, with data often aggregated to number of doses or number of drugs per unit population, attributing any reduction to cessation. Such studies are not measuring the actual required outcome (stopping prescribing), and this may reflect the broader ambiguity about when or why it might be important to end a prescription. Much more research is required into the process of stopping pre-existing prescribing, paying particular attention to improving the outcomes that are measured.
Collapse
|
39
|
Lessing C, Schmitz A, Albers B, Schrappe M. Impact of sample size on variation of adverse events and preventable adverse events: systematic review on epidemiology and contributing factors. Qual Saf Health Care 2010; 19:e24. [PMID: 20679137 PMCID: PMC3002821 DOI: 10.1136/qshc.2008.031435] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/02/2009] [Indexed: 11/04/2022]
Abstract
OBJECTIVES To perform a systematic review of the frequency of (preventable) adverse events (AE/PAE) and to analyse contributing factors, such as sample size, settings, type of events, terminology, methods of collecting data and characteristics of study populations. REVIEW METHODS Search of Medline and Embase from 1995 to 2007. Included were original papers with data on the frequency of AE or PAE, explicit definition of study population and information about methods of assessment. Results were included with percentages of patients having one or more AE/PAE. Extracted data enclosed contributing factors. Data were abstracted and analysed by two researchers independently. RESULTS 156 studies in 152 publications met our inclusion criteria. 144/156 studies reported AE, 55 PAE (43 both). Sample sizes ranged from 60 to 8,493,876 patients (median: 1361 patients). The reported results for AE varied from 0.1% to 65.4%, and for PAE from 0.1% to 33.9%. Variation clearly decreased with increasing sample size. Estimates did not differ according to setting, type of event or terminology. In studies with fewer than 1000 patients, chart review prevailed, whereas surveys with more than 100,000 patients were based mainly on administrative data. No effect of patient characteristics was found. CONCLUSIONS The funnel-shaped distribution of AE and PAE rates with sample size is a probable consequence of variation and can be taken as an indirect indicator of study validity. A contributing factor may be the method of data assessment. Further research is needed to explain the results when analysing data by types of event or terminology.
Collapse
Affiliation(s)
- Constanze Lessing
- Institute for Patient Safety, University of Bonn, D-53111 Bonn, Germany.
| | | | | | | |
Collapse
|
40
|
Zaal RJ, van Doormaal JE, Lenderink AW, Mol PGM, Kosterink JG, Egberts TCG, Haaijer-Ruskamp FM, van den Bemt PMLA. Comparison of potential risk factors for medication errors with and without patient harm. Pharmacoepidemiol Drug Saf 2010; 19:825-33. [DOI: 10.1002/pds.1977] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
41
|
Quenon JL, Perret F, Faraggi L, De Sarasqueta AM. [Security in medication use process: state-of-play report in 21 hospital pharmacies in Aquitaine (France)]. Therapie 2009; 64:303-11. [PMID: 19863905 DOI: 10.2515/therapie/2009052] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2008] [Accepted: 08/25/2009] [Indexed: 11/20/2022]
Abstract
BACKGROUND Failures may occur in each part of the medication use process. This study aimed to evaluate the barriers existing in hospital pharmacies in order to prevent medication errors and to help institutions to make improvement actions. METHODS Within the framework of the SECURIMED project, risk assessment visit (interviews, observations, analysis of adverse event scenario by professionals...) were conducted in volunteer hospital pharmacies. A restitution meeting, after visit in each pharmacy permitted exchanges between visitors and professionals on barriers and weaknesses and then on solutions to reduce identified risks. RESULTS Twenty-one hospital pharmacies participated. Despite presence of safeguards in some pharmacies, many weaknesses were retrieved (multiplicity of process, lack of resources...) and clinical pharmacy was not enough developed. CONCLUSION This project has led to an overview of the situation in Aquitaine, and created a regional dynamic to improve the medication system safety.
Collapse
|
42
|
Zidarn M, Silar M, Vegnuti M, Korosec P, Kosnik M. The specificity of tests for anti-beta-lactam IgE antibodies declines progressively with increase of total serum IgE. Wien Klin Wochenschr 2009; 121:353-6. [PMID: 19562301 DOI: 10.1007/s00508-009-1187-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND Immediate allergic reactions to beta-lactam antibiotics are mediated by specific IgE antibodies. The Phadia CAP System FEIA is a commercial method for quantification of specific IgE. We wished to determine anti-beta-lactam IgE antibodies in patients without penicillin allergy but with high levels of total IgE. METHODS Sera from 41 patients (31 with high total IgE, 10 with low total IgE) were analyzed for IgE antibodies specific to penicilloyl G, penicilloyl V, amoxicilloyl and ampicilloyl using the CAP FEIA((R)) method that was available up to 2006. Seven sera that tested positive were rechecked in a new improved system available after 2006. RESULTS In patients without a history of penicillin allergy, the specificities of commercial tests for anti-beta-lactam IgE antibodies were 100%, 60%, 27% and 20% at total IgE levels of 8-263 kU/l, 500-664 kU/l, 1000-2000 kU/l and > 2000 kU/l, respectively. In seven retested sera, only 2 (28%) were still positive for penicillin-specific IgE antibody. CONCLUSION Before 2006, tests for anti-beta-lactam IgE antibody in patients with total IgE > 500 kU/l were probably often false positive. Patients who were diagnosed as penicillin allergic before 2006 solely on the basis of a positive CAP FEIA test for specific IgE should be considered for diagnostic reevaluation.
Collapse
Affiliation(s)
- Mihaela Zidarn
- University Clinic of Respiratory and Allergic Diseases Golnik, Slovenia.
| | | | | | | | | |
Collapse
|
43
|
Schwappach DLB, Wernli M. Medication errors in chemotherapy: incidence, types and involvement of patients in prevention. A review of the literature. Eur J Cancer Care (Engl) 2009; 19:285-92. [PMID: 19708929 DOI: 10.1111/j.1365-2354.2009.01127.x] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Medication errors in chemotherapy occur frequently and have a high potential to cause considerable harm. The objective of this article is to review the literature of medication errors in chemotherapy, their incidences and characteristics, and to report on the growing evidence on involvement of patients in error prevention. Among all medication errors and adverse drug events, administration errors are common. Current developments in oncology, namely, increased outpatient treatment at ambulatory infusion units and the diffusion of oral chemotherapy to the outpatient setting, are likely to increase hazards since the process of preparing and administering the drug is often delegated to patients or their caregivers. While professional activities to error incidence reduction are effective and important, it has been increasingly acknowledged that patients often observe errors in the administration of drugs and can thus be a valuable resource in error prevention. However, patients need appropriate information, motivation and encouragement to act as 'vigilant partners'. Examples of simple strategies to involve patients in their safety are presented. Evidence indicates that high self-efficacy and perceived effectiveness of the specific preventive actions increase likelihood of participation in error prevention. Clinicians play a crucial role in supporting and enabling the chemotherapy patient in approaching errors.
Collapse
Affiliation(s)
- D L B Schwappach
- Swiss Patient Safety Foundation, Zuerich, Switzerland, and Faculty of Medicine, University Witten-Herdecke, Witten, Germany.
| | | |
Collapse
|
44
|
Schedlbauer A, Prasad V, Mulvaney C, Phansalkar S, Stanton W, Bates DW, Avery AJ. What evidence supports the use of computerized alerts and prompts to improve clinicians' prescribing behavior? J Am Med Inform Assoc 2009; 16:531-8. [PMID: 19390110 DOI: 10.1197/jamia.m2910] [Citation(s) in RCA: 186] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Alerts and prompts represent promising types of decision support in electronic prescribing to tackle inadequacies in prescribing. A systematic review was conducted to evaluate the efficacy of computerized drug alerts and prompts searching EMBASE, CINHAL, MEDLINE, and PsychINFO up to May 2007. Studies assessing the impact of electronic alerts and prompts on clinicians' prescribing behavior were selected and categorized by decision support type. Most alerts and prompts (23 out of 27) demonstrated benefit in improving prescribing behavior and/or reducing error rates. The impact appeared to vary based on the type of decision support. Some of these alerts (n = 5) reported a positive impact on clinical and health service management outcomes. For many categories of reminders, the number of studies was very small and few data were available from the outpatient setting. None of the studies evaluated features that might make alerts and prompts more effective. Details of an updated search run in Jan 2009 are included in the supplement section of this review.
Collapse
Affiliation(s)
- Angela Schedlbauer
- Division of Primary Care, School of Community Health Sciences, Research and Learning Resources Division, Information Services, University of Nottingham, Nottingham, UK.
| | | | | | | | | | | | | |
Collapse
|
45
|
Müller M. Polypharmacy, inappropriate prescribing and adverse drug reactions in Austria. Wien Klin Wochenschr 2009; 120:713-4. [PMID: 19122980 DOI: 10.1007/s00508-008-1106-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
46
|
Mollon B, Chong J, Holbrook AM, Sung M, Thabane L, Foster G. Features predicting the success of computerized decision support for prescribing: a systematic review of randomized controlled trials. BMC Med Inform Decis Mak 2009; 9:11. [PMID: 19210782 PMCID: PMC2667396 DOI: 10.1186/1472-6947-9-11] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2008] [Accepted: 02/11/2009] [Indexed: 11/10/2022] Open
Abstract
Background Computerized decision support systems (CDSS) are believed to have the potential to improve the quality of health care delivery, although results from high quality studies have been mixed. We conducted a systematic review to evaluate whether certain features of prescribing decision support systems (RxCDSS) predict successful implementation, change in provider behaviour, and change in patient outcomes. Methods A literature search of Medline, EMBASE, CINAHL and INSPEC databases (earliest entry to June 2008) was conducted to identify randomized controlled trials involving RxCDSS. Each citation was independently assessed by two reviewers for outcomes and 28 predefined system features. Statistical analysis of associations between system features and success of outcomes was planned. Results Of 4534 citations returned by the search, 41 met the inclusion criteria. Of these, 37 reported successful system implementations, 25 reported success at changing health care provider behaviour, and 5 noted improvements in patient outcomes. A mean of 17 features per study were mentioned. The statistical analysis could not be completed due primarily to the small number of studies and lack of diversity of outcomes. Descriptive analysis did not confirm any feature to be more prevalent in successful trials relative to unsuccessful ones for implementation, provider behaviour or patient outcomes. Conclusion While RxCDSSs have the potential to change health care provider behaviour, very few high quality studies show improvement in patient outcomes. Furthermore, the features of the RxCDSS associated with success (or failure) are poorly described, thus making it difficult for system design and implementation to improve.
Collapse
Affiliation(s)
- Brent Mollon
- The Centre for Evaluation of Medicines, McMaster University, Hamilton, Ontario, Canada.
| | | | | | | | | | | |
Collapse
|
47
|
Rissato MDAR, Romano-Lieber NS, Lieber RR. Terminologia de incidentes com medicamentos no contexto hospitalar. CAD SAUDE PUBLICA 2008; 24:1965-75. [DOI: 10.1590/s0102-311x2008000900002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2008] [Accepted: 07/01/2008] [Indexed: 11/22/2022] Open
Abstract
Incidentes com medicamentos geram problemas aos pacientes e custos adicionais ao sistema de saúde. A variedade de termos utilizada para comunicá-los propicia divergências nos resultados de pesquisas e confundem notificadores. Objetivou-se revisar os termos utilizados para descrever estes incidentes confrontando-os com as conceituações/definições oficiais disponíveis. Pesquisaram-se as bases PubMed, MEDLINE, IPA e LILACS para selecionar estudos publicados entre janeiro de 1990 e dezembro de 2005. Selecionaram-se 33 publicações. Verificou-se que a terminologia supranacional recomendada para descrever incidentes com medicamentos é insuficiente, mas que há consenso de uso das expressões em função do gênero do incidente. O termo Reação Adversa a Medicamento é mais utilizado quando não se verifica intencionalidade. A expressão Evento Adverso a Medicamento foi mais usada quando se descreviam incidentes durante a hospitalização; e Problema Relacionado a Medicamento foi mais utilizada em estudos que avaliaram atenção/cuidados farmacêuticos (uso/falta do medicamento). Ainda assim, a linha divisória entre essas três categorias não é clara e simples. Futuros estudos das relações entre as categorias e investigações multidisciplinares sobre erro humano podem subsidiar a proposição de novas conceituações.
Collapse
|
48
|
Zancan A, Locatelli C, Ramella F, Tatoni P, Bacis G, Vecchio S, Manzo L. A new model of pharmacovigilance? A pilot study. Biomed Pharmacother 2008; 63:451-5. [PMID: 18790597 DOI: 10.1016/j.biopha.2008.07.091] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2008] [Accepted: 07/30/2008] [Indexed: 11/15/2022] Open
Abstract
This multicenter study tested the actuation of a new model of pharmacovigilance, focused on three pharmacological wide-used categories (non-steroidal anti-inflammatory drugs, NSAID, oral anticoagulants, and antihypertensive drugs). Besides the traditional way of pharmacovigilance, an active investigation was performed, using a phone-structured interview. Patients discharged from the participating hospitals were included into the study, if their prescribed therapy included some of the above drugs and after informed consent. Three hundred subjects were interviewed, 100 for each pharmacological category. For a period of six months after patient's discharge from the hospital, a traditional pharmacovigilance survey was carried out. About 30 days after discharge from the hospital, patients were interviewed by the medical staff and data recorded. NSAID group stratification evidenced a significant percentage of severe haemorrhage among the patients who were using acetylsalicylic acid (ASA) as antiaggregant (6.8%) compared to the patients who were using non-ASA NSAID, at therapeutic dosage (1.8%). From this data, it seems that the active pharmacovigilance model was able to better highlight a real problem for the NSAID category, in particular it evidenced a pharmacological subclass (ASA) more prone to cause ADR than expected from literature data related to whole pharmacological class. Given the required economical effort, this pharmacovigilance method could take place as a selected tool when pharmacovigilance signals from the international databases become consistent or for new wide-used drugs, to screen potentially dangerous pharmacological subclasses, normally "hidden" because of a "camouflage" among ADRs of the entire pharmacological class.
Collapse
Affiliation(s)
- A Zancan
- Fondazione Maugeri IRCCS, Pavia, Italy.
| | | | | | | | | | | | | |
Collapse
|
49
|
A nurse-led intervention for identification of drug-related problems. Eur J Clin Pharmacol 2008; 64:451-6. [PMID: 18204835 DOI: 10.1007/s00228-007-0449-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2007] [Accepted: 12/13/2007] [Indexed: 10/22/2022]
|
50
|
Rommers MK, Teepe-Twiss IM, Guchelaar HJ. Preventing adverse drug events in hospital practice: an overview. Pharmacoepidemiol Drug Saf 2007; 16:1129-35. [PMID: 17610221 DOI: 10.1002/pds.1440] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Adverse drug events (ADEs) are a considerable cause of morbidity and mortality in hospital practice. The precise frequency is unknown, but studies give an incidence number ranging from 2 until 52 ADEs per 100 patients. There are many different methods for definition, causality assessment, severity classification and detection which make it difficult to compare the different studies. A substantial part (in some studies up to 70%) of ADEs can be prevented and it is important to, besides their detection, focus on the prevention of these ADEs. In this literature review we give an overview of methods for preventing ADEs. There are many different tools with different impact on a particular part of the distribution system which has the potential to prevent ADEs. A multifaceted approach is needed. Two interesting strategies of prevention, pharmacist participation on ward rounds and computerised physician order entry with clinical decision support systems (CDSS), are highlighted. Moreover, two promising CDSS are discussed in more detail, namely computer-based monitoring systems and information systems which link laboratory and pharmacy data.
Collapse
Affiliation(s)
- Mirjam K Rommers
- Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, The Netherlands.
| | | | | |
Collapse
|